Literature DB >> 3672875

Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy.

C R Sweeney1, R W Sweeney, T J Divers.   

Abstract

Case records of 48 foals with pneumonia due to Rhodococcus equi were reviewed. Twenty of the 48 foals survived and 28 died or were euthanized. There was no significant difference between the survivors and non-survivors in the age of onset of illness, duration of illness prior to admission, the mean white blood cell (WBC) count, or the mean plasma fibrinogen content. All foals had R. equi isolated from a tracheobronchial aspirate or lung specimens obtained at necropsy. All organisms were susceptible in vitro (Kirby-Bauer) to erythromycin and gentamicin. Susceptibilities to other drugs were: trimethoprim-sulfamethoxazole (88%), tetracycline (87%), chloramphenicol (83%); 97% were resistant to cephalothin and 83% to penicillin. Thirteen of the 20 surviving foals were treated with erythromycin and/or rifampin. A decline in mortality rate was observed with the introduction of the combination of erythromycin and rifampin. None of the 17 foals treated with penicillin and gentamicin survived. Chronic, active, non-septic synovitis was confirmed in 17 foals. These foals had joint distension with mild or no apparent lameness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3672875     DOI: 10.1016/0378-1135(87)90120-9

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  19 in total

1.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

2.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Emergence of rifampin-resistant Rhodococcus equi in an infected foal.

Authors:  S Takai; K Takeda; Y Nakano; T Karasawa; J Furugoori; Y Sasaki; S Tsubaki; T Higuchi; T Anzai; R Wada; M Kamada
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

4.  In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.

Authors:  Stephanie S Jacks; Steeve Giguère; An Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Spectrum of disease caused by Rhodococcus equi in human immunodeficiency virus infection: Report of a case and review of the literature.

Authors:  S K Willsie-Ediger; J F Stanford; G A Salzman; D M Bamberger
Journal:  Can J Infect Dis       Date:  1990

Review 6.  Rhodococcus equi: an animal and human pathogen.

Authors:  J F Prescott
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Comparison of nucleic acid amplification, serology, and microbiologic culture for diagnosis of Rhodococcus equi pneumonia in foals.

Authors:  D C Sellon; T E Besser; S L Vivrette; R S McConnico
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  Rhodococcus equi pleuropneumonia in an adult horse.

Authors:  Modest Vengust; Henry Staempfli; John F Prescott
Journal:  Can Vet J       Date:  2002-09       Impact factor: 1.008

9.  Prevention of foal mortality due to Rhodococcus equi pneumonia on an endemically affected farm.

Authors:  J F Prescott; R Machang'u; J Kwiecien; K Delaney
Journal:  Can Vet J       Date:  1989-11       Impact factor: 1.008

Review 10.  Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-14       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.